I am due to start the third part of my 'triple' plan on Monday and am signed up for abiraterone (zytiga) with prednisolone. My 'triple' initial plan for my PCa which spread to the spine and rib last year has already changed from:
Degarelix
LU-177 (personal choice to replace chemo though i am hormone sensitive
Abitraterone
to
Degarelix
Lu-177 x 3 plus Chemo x 3 ( Onco recommendation)
Second hormone therapy drug
I have been on Degarelix since 25th November, completed 3 x LU-177 (PSA drop from 17.6- 0.55 after second LU-177, so fingers crossed third one has dropped it further). 1st Chemo on 7th March.
My Lu-177 onco would prefer me to start Enzalutamide (Xanti) instead to avoid prednisolone.
My understanding is my private healthcare cover will pay for either- any advice here as my London onco prefers Abi!
With the Arasens clinical trial publishing yesterday should I push for Darolutamide if I can access it or just go with Abi or Enza?
Then there is Apalutamide (Erleada) , approved last Sept in UK for HSMPC if docetaxel is not suitable ( I'm not having it in the UK but overseas and out of pocket) or 'according to the commercial arrangement'.
Ideally I would like to use my insurance or the NHS for the cost of my second hormone therapy drug.
Any thoughts on what's worth asking about?
If i stick with Abi v Enza - which one?